Repligen (NASDAQ:RGEN) Coverage Initiated at Barclays

Stock analysts at Barclays assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $150.00 price target on the biotechnology company’s stock. Barclays‘s price target would suggest a potential upside of 20.95% from the stock’s previous close.

Several other research analysts also recently commented on the company. Wall Street Zen upgraded Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, June 21st. Wolfe Research raised Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target for the company in a report on Tuesday, April 29th. Evercore ISI assumed coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective on the stock. Canaccord Genuity Group dropped their price objective on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research report on Wednesday, April 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $171.46.

Repligen Stock Performance

Shares of RGEN opened at $124.02 on Tuesday. The company has a market cap of $6.97 billion, a PE ratio of -275.60, a price-to-earnings-growth ratio of 3.53 and a beta of 1.10. The firm has a 50-day moving average of $128.34 and a 200-day moving average of $141.43. Repligen has a one year low of $102.97 and a one year high of $182.52. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. Repligen’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS. As a group, equities analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Institutional investors have recently modified their holdings of the business. Signaturefd LLC raised its stake in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen during the fourth quarter worth approximately $29,000. Raiffeisen Bank International AG bought a new position in shares of Repligen during the fourth quarter worth approximately $29,000. Twin Tree Management LP acquired a new stake in shares of Repligen in the first quarter valued at approximately $29,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Repligen in the fourth quarter valued at approximately $40,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.